Indication
NRAS
6 clinical trials
11 products
Product
OKI-179Clinical trial
NAUTILUS: A Phase 1b/2 Study of OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors and Activating Mutations in the RAS Pathway (Phase 1b) and in Patients With Advanced NRAS-Mutated Melanoma (Phase 2)Status: Active (not recruiting), Estimated PCD: 2026-03-04
Product
ELI-002Clinical trial
First in Human Phase 1 Trial of ELI-002 Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS) Mutated Pancreatic Ductal Adenocarcinoma and Other Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2023-01-26
Product
BDTX-4933Clinical trial
A Phase 1, Open-label Study of Oral BDTX-4933 in Patients With KRAS, BRAF and Other Select RAS/MAPK Mutation Positive NeoplasmsStatus: Recruiting, Estimated PCD: 2026-06-01
Product
OKI-179 + binimetinibProduct
RMC-6291Clinical trial
A Platform Study of RAS(ON) Inhibitor Combinations in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2027-06-01
Product
PembrolizumabProduct
CarboplatinProduct
RMC-6236Product
CisplatinProduct
PemetrexedProduct
UlixertinibClinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered MalignanciesStatus:
Clinical trial
First in Human Phase 1/2 Trial of ELI-002 7P Immunotherapy as Treatment for Subjects With Kirsten Rat Sarcoma (KRAS)/Neuroblastoma RAS Viral Oncogene Homolog (NRAS) Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsStatus: Recruiting, Estimated PCD: 2026-11-01